Hims and Hers enters Canadian market

By mlecer 26/05/2026 2 min read 85 views

Hims & Hers is now offering generic semaglutide in Canada through its direct-to-consumer virtual care platform, following the loss of patent protection for Ozempic and Wegovy by Novo Nordisk in the country. The company provides a range of health services, including weight loss and GLP-1 treatments, mental health care, and women’s health services.

The expansion into Canada allows eligible customers to access personalized care plans that include generic semaglutide options, starting at CAD 149 ($107 USD) per month. Customers will also have unlimited access to a Canadian care team and resources focused on sleep, movement, and nutrition, which can be part of a broader initial public offering strategy.

Austin Kouri, managing director at Hims & Hers Canada, stated that the company is committed to supporting and strengthening Canada’s healthcare system. He added that bringing generic semaglutide to the market means more Canadians will have access to this treatment at an affordable price.

Generic Semaglutide Approval in Canada

In April, Health Canada announced its first authorization of a generic semaglutide, filed by Dr. Reddy’s Laboratories. This was the first approval of its kind in the G7. The agency is currently reviewing eight other submissions for generic semaglutide from different companies.

Reporters noted that the U.S. Food and Drug Administration has also taken action related to GLP-1 weight-loss drugs, issuing a warning to consumers about unapproved and compounded products containing semaglutide, tirzepatide, or retatrutide.

Novo Nordisk had previously filed a lawsuit against Hims & Hers, alleging patent infringement and misleading consumers. However, the lawsuit was dismissed without prejudice, and the two companies announced a strategic partnership to allow Hims to sell Ozempic and Wegovy through its platform.

Partnership and Compounded GLP-1 Offerings

As part of the partnership, Hims & Hers will no longer advertise compounded GLP-1 offerings on its platform or in its marketing. Existing patients will have the opportunity to transition to FDA-approved medicines when determined clinically appropriate by their providers.

For a limited set of customers whose clinical needs cannot be met using commercially available FDA-approved GLP-1s, they plan to offer access to compounded GLP-1s if a provider determines that a compounded product is clinically necessary.

Novo Nordisk lost its patent protection in Canada for Ozempic and Wegovy after failing to pay a small fee to maintain it. This loss of patent protection has allowed other companies, such as Hims & Hers, to offer generic versions of semaglutide in the country.

The company’s expansion into Canada is part of its efforts to support and strengthen the country’s healthcare system. It is expected to increase access to this treatment for Canadians, making it more affordable and widely available.